Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of glofitamab plus GemOx versus rituximab plus GemOx in relapsed/refractory DLBCL
2020-001021-31Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) and B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Roche. Primary endpoint: Overall Survival. Started Aug 2020; status: active.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2020-001021-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001021-31.